Halozyme Therapeutics (NASDAQ:HALO) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 2 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 3 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 2 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $53.71, a high estimate of $72.00, and a low estimate of $50.00. Witnessing a positive shift, the current average has risen by 11.9% from the previous average price target of $48.00.
Diving into Analyst Ratings: An In-Depth Exploration
A clear picture...
Login or create a forever free account to read this news
Sign up/Log in